Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021

May 13, 2021 Auto Bot cervical cancer, Clinical Trials, Libtayo, P-III, Regeneron, Sanofi, Trial 0

Shots:

  • The P-III trial involves assessing libtayo (300mg, IV, q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The companies expect the regulatory submission in 2021
  • The results demonstrated a 31% reduction in the risk of death in the total population, improvement in OS, PFS, and ORR (16% vs 6%), mDoR (16 mos. vs 7 mos.), and 25% reduction in the risk of disease progression
  • Libtayo is a fully human mAb targeting the immune checkpoint receptor PD-1 on T-cells. The use of Libtayo for advanced cervical cancer is investigational and has not been fully reviewed by any regulatory authority

Click here to­ read full press release/ article | Ref: Regeneron | Image: Regeneron

The post Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021 first appeared on PharmaShots.